Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M Haynes, Kathryn Kinross, Hideo Yagita, Richard C Koya, Thomas G Graeber, Antoni Ribas, Grant A McArthur, Mark J Smyth
JOURNAL OF CLINICAL INVESTIGATION | AMER SOC CLINICAL INVESTIGATION INC | Published : 2013
Related Projects (3)
Awarded by National Health and Medical Research Council of Australia (NHMRC) program
Awarded by Grants-in-Aid for Scientific Research
Grant A. McArthur declares financial research support from Pfizer and Millenium.We thank Qerime Mundrea for her care and maintenance of the mouse colonies. The vemurafenib analog PLX4720 was provided by Gideon Bollag from Plexxikon Inc. This work was supported by the National Health and Medical Research Council of Australia (NHMRC) program grant (454569) and project grant (1002655) and the Victorian Cancer Agency. M.J. Smyth received support from a NHMRC Australia Fellowship. S.F. Ngiow was supported by a Cancer Research Institute PhD scholarship. G.A. McArthur received support from a NHMRC Practitioner Fellowship.